Crinetics Pharmaceuticals, Inc. (CRNX) Current Ratio
- Current ratio · latest quarter: Value 15.57×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 15.57× | Current assets / current liabilities. $1.24B ÷ $79.92M ≈ 15.57× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.24B USD | Assets, Current |
| Current obligations | 79.92M USD | Liabilities, Current |
| Cash and equivalents | 55.50M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 11.96M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 3.49M USD | Inventory, Net |
| Payables | 13.25M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.24B | $79.92M | $55.50M | (m) | $11.96M | $3.49M | $13.25M | (m) | 15.57× |
| 2026-03-31 | $1.32B | $71.09M | $114.34M | (m) | $5.68M | $3.06M | $12.88M | (m) | 18.60× |
| 2025-12-31 | $1.05B | $85.07M | $101.54M | (m) | $592.00K | $2.02M | $22.61M | (m) | 12.32× |
| 2025-09-30 | $1.12B | $74.16M | $110.90M | (m) | (m) | (m) | $6.11M | (m) | 15.12× |
| 2025-06-30 | $1.22B | $68.40M | $53.73M | $357.75M | (m) | (m) | $11.32M | (m) | 17.80× |
| 2025-03-31 | $1.29B | $57.31M | $94.57M | $273.93M | (m) | (m) | $9.84M | (m) | 22.53× |
| 2024-12-31 | $1.38B | $59.68M | $264.55M | (m) | $0.00 | $0.00 | $5.85M | (m) | 23.04× |
| 2024-09-30 | $877.59M | $53.56M | $317.27M | $40.80M | (m) | (m) | $4.94M | (m) | 16.38× |
| 2024-06-30 | $874.78M | $54.38M | $302.16M | $350.84M | (m) | (m) | $8.87M | (m) | 16.09× |
| 2024-03-31 | $917.23M | $51.77M | $395.92M | $205.25M | (m) | (m) | $10.76M | (m) | 17.72× |
| 2023-12-31 | $574.15M | $43.94M | $54.90M | $74.09M | (m) | (m) | $6.55M | (m) | 13.07× |
| 2023-09-30 | $575.76M | $40.46M | $142.79M | $307.14M | (m) | (m) | $5.84M | (m) | 14.23× |
| 2023-06-30 | $284.81M | $32.61M | $39.55M | $167.85M | (m) | (m) | $4.84M | (m) | 8.73× |
| 2023-03-31 | $305.40M | $26.32M | $41.19M | $209.05M | (m) | (m) | $5.89M | (m) | 11.60× |
| 2022-12-31 | $345.18M | $27.72M | $32.67M | $278.64M | (m) | (m) | $6.88M | (m) | 12.45× |
| 2022-09-30 | $378.32M | $24.56M | $30.91M | (m) | (m) | (m) | $5.88M | (m) | 15.41× |
| 2022-06-30 | $416.29M | $26.11M | $62.29M | (m) | (m) | (m) | $9.04M | (m) | 15.94× |
| 2022-03-31 | $328.25M | $20.26M | $145.55M | (m) | (m) | (m) | (m) | (m) | 16.20× |
| 2021-12-31 | $344.72M | $15.99M | $200.69M | (m) | (m) | (m) | $3.42M | (m) | 21.55× |
| 2021-09-30 | $203.97M | $12.44M | $161.54M | (m) | (m) | (m) | (m) | (m) | 16.40× |
| 2021-06-30 | $211.35M | $11.92M | $178.77M | (m) | (m) | (m) | (m) | (m) | 17.73× |
| 2021-03-31 | $157.80M | $10.26M | $105.58M | (m) | (m) | (m) | (m) | (m) | 15.37× |
| 2020-12-31 | $177.49M | $10.49M | $93.09M | (m) | (m) | (m) | (m) | (m) | 16.92× |
| 2020-09-30 | $194.12M | $8.83M | $117.82M | (m) | (m) | (m) | (m) | (m) | 21.98× |
| 2020-06-30 | $210.61M | $9.87M | $160.81M | (m) | (m) | (m) | (m) | (m) | 21.34× |
| 2020-03-31 | $117.17M | $10.76M | $50.92M | (m) | (m) | (m) | (m) | (m) | 10.89× |
| 2019-12-31 | $123.34M | $8.34M | $40.33M | (m) | (m) | (m) | (m) | (m) | 14.79× |
| 2019-09-30 | $135.40M | $7.88M | $66.58M | (m) | (m) | (m) | $2.11M | (m) | 17.18× |
| 2019-06-30 | $147.76M | $7.75M | $59.72M | (m) | (m) | (m) | $2.71M | (m) | 19.07× |
| 2019-03-31 | $159.12M | $8.82M | $62.83M | (m) | (m) | (m) | $2.00M | (m) | 18.04× |
| 2018-12-31 | $166.68M | $7.92M | $44.97M | (m) | (m) | (m) | (m) | (m) | 21.03× |
| 2018-09-30 | $171.04M | $5.51M | $169.65M | (m) | (m) | (m) | $1.40M | (m) | 31.02× |
| 2018-06-30 | $69.94M | $5.64M | $68.41M | (m) | (m) | (m) | $2.60M | (m) | 12.41× |
| 2017-12-31 | $15.16M | $897.00K | $14.19M | (m) | (m) | (m) | $403.00K | (m) | 16.91× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.